secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sionna Therapeutics, Inc. (SION)
CIK:        0002036042
Form:       8-K
Filed at:   2026-08-06T11:12:37+00:00
Accession:  0001628280-26-053832
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sionna Therapeutics Q2 2026 net loss $29.9M; cash $268.3M; Phase 2a and Phase 1 trials on track for summer data
--------------------------------------------------------------------------------

- Net loss of $29.9M for Q2 2026, compared to $18.1M in Q2 2025.
- R&D expenses $21.9M (up from $15.4M) and G&A $10.6M (up from $6.5M) driven by pipeline advancement.
- Cash and equivalents $268.3M as of June 30, 2026, expected to fund operations into 2028.
- PreciSION CF Phase 2a trial of SION-719 as add-on to standard of care on track for topline data summer 2026.
- Phase 1 trial of SION-451 in dual combinations with SION-2222 and SION-109 also on track for topline data summer 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2036042/000162828026053832/0001628280-26-053832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2036042/000162828026053832/sion-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer